Cardiovascular and renal effects of bromocriptine in diabetic patients with stage 4 chronic kidney disease

BioMed Research International

Volumn 2013, Issue , 2013, Pages

  Mejía Rodríguez, Oliva ^a,b   Herrera Abarca, Jorge E ^b   Ceballos Reyes, Guillermo ^b   Avila Diaz, Marcela ^a   Prado Uribe, Carmen ^a   Belio Caro, Francisco ^c   Salinas González, Antonio ^c   Vega Gomez, Helios ^c   Alvarez Aguilar, Cleto ^c   Lindholm, Bengt ^d   García López, Elvia ^d   Paniagua, Ramón ^a  

^a INSTITUTO MEXICANO DEL SEGURO SOCIAL   (Mexico)

^b INSTITUTO POLITÉCNICO NACIONAL   (Mexico)

^c Hospital General Regional No 1 IMSS   (Mexico)

^d KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BROMOCRIPTINE MESILATE; CREATININE; CYSTATIN C; PLACEBO; BROMOCRIPTINE; HORMONE ANTAGONIST;

ADULT; AGED; ARTICLE; BLOOD PRESSURE MONITORING; CARDIOVASCULAR EFFECT; CHRONIC KIDNEY DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; CREATININE CLEARANCE; DIABETIC PATIENT; DRUG EFFECT; FEMALE; HEART LEFT VENTRICLE MASS; HUMAN; KIDNEY FUNCTION; M MODE ECHOCARDIOGRAPHY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PROTEIN BLOOD LEVEL; BLOOD PRESSURE; CHRONIC KIDNEY FAILURE; CONTROLLED CLINICAL TRIAL; DEMOGRAPHY; ECHOCARDIOGRAPHY; HEART; HEART VENTRICLE; KIDNEY; MIDDLE AGED; ORGAN SIZE; PATHOLOGY; PATHOPHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL; COMPLICATION; DIABETES MELLITUS, TYPE 2; DRUG EFFECTS; RENAL INSUFFICIENCY, CHRONIC;

BLOOD PRESSURE; BLOOD PRESSURE MONITORING, AMBULATORY; BROMOCRIPTINE; DEMOGRAPHY; DIABETES MELLITUS, TYPE 2; ECHOCARDIOGRAPHY; FEMALE; HEART; HEART VENTRICLES; HORMONE ANTAGONISTS; HUMANS; KIDNEY; MALE; MIDDLE AGED; ORGAN SIZE; PLACEBOS; RENAL INSUFFICIENCY, CHRONIC;

EID: 84883174324     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2013/104059     Document Type: Article

References (40)

1. US Renal Data System, USRDS 2004 Annual Data Report: Atlas of End-Stage Renal Disease in the United States. National Institute of Health. National Institute of Diabetes and Digestive and Kidney Diseases 2004 Bethesda, Md, USA
2. McMahon L. P., Parfrey P. S., Brenner B. M., Cardiovascular aspects of chronic kidney disease. Brenner & Rector's the Kidney 2008 8th Philadelphia, Pa, USA Saunders Elsevier 1697 1727
3. Schiffrin E. L., Lipman M. L., Mann J. F. E., Chronic kidney disease: effects on the cardiovascular system. Circulation 2007 116 1 85 97 2-s2.0-34347350171 10.1161/CIRCULATIONAHA.106.678342
4. Parfrey P. S., Foley R. N., Harnett J. D., Kent G. M., Murray D. C., Barre P. E., Outcome and risk factors for left ventricular disorders in chronic uraemia. Nephrology Dialysis Transplantation 1996 11 7 1277 1285 2-s2.0-0029900359
5. Fagugli R. M., Pasini P., Quintaliani G., Pasticci F., Ciao G., Cicconi B., Ricciardi D., Santirosi P. V., Buoncristiani E., Timio F., Valente F., Buoncristiani U., Association between extracellular water, left ventricular mass and hypertension in haemodialysis patients. Nephrology Dialysis Transplantation 2003 18 11 2332 2338 2-s2.0-10744226879 10.1093/ndt/gfg371
6. Sarnak M. J., Greene T., Wang X., Beck G., Kusek J. W., Collins A. J., Levey A. S., The effect of a lower target blood pressure on the progression of kidney disease: long-term follow-up of the modification of diet in renal disease study. Annals of Internal Medicine 2005 142 5 342 351 2-s2.0-14344255910
7. Schrier R. W., Estacio R. O., Esler A., Mehler P., Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes. Kidney International 2002 61 3 1086 1097 2-s2.0-0036190137 10.1046/j.1523-1755.2002.00213.x
8. Silberberg J. S., Barre P. E., Prichard S. S., Sniderman A. D., Impact of left ventricular hypertrophy on survival in end-stage renal disease. Kidney International 1989 36 2 286 290 2-s2.0-0024324631
9. Foley R. N., Parfrey P. S., Harnett J. D., Kent G. M., Murray D. C., Barre P. E., The prognostic importance of left ventricular geometry in uremic cardiomyopathy. Journal of the American Society of Nephrology 1995 5 12 2024 2031 2-s2.0-0029054217
10. Ruggenenti P., Cravedi P., Remuzzi G., The RAAS in the pathogenesis and treatment of diabetic nephropathy. Nature Reviews 2010 6 6 319 330 2-s2.0-77956644609 10.1038/nrneph.2010.58
11. Henrich W. L., Optimal cardiovascular therapy for patients with ESRD over the next several years. Clinical Journal of the American Society of Nephrology 2009 4 supplement 1 S106 S109 2-s2.0-73849136046 10.2215/CJN.04640709
12. Masuo K., Lambert G. W., Esler M. D., Rakugi H., Ogihara T., Schlaich M. P., The role of sympathetic nervous activity in renal injury and end-stage renal disease. Hypertension Research 2010 33 6 521 528 2-s2.0-77953200567 10.1038/hr.2010.35
13. Rump L. C., Amann K., Orth S., Ritz E., Sympathetic overactivity in renal disease: a window to understand progression and cardiovascular complications of uraemia? Nephrology Dialysis Transplantation 2000 15 11 1735 1738 2-s2.0-0033760176
14. Schlaich M. P., Socratous F., Hennebry S., Eikelis N., Lambert E. A., Straznicky N., Esler M. D., Lambert G. W., Sympathetic activation in chronic renal failure. Journal of the American Society of Nephrology 2009 20 5 933 939 2-s2.0-65649109067 10.1681/ASN.2008040402
15. Elias A. N., Vaziri N. D., Maksy M., Plasma norepinephrine, epinephrine, and dopamine levels in end-stage renal disease. Effect of hemodialysis. Archives of Internal Medicine 1985 145 6 1013 1015 2-s2.0-0021828617 10.1001/archinte.145.6.1013
16. Ziegler M. G., Kennedy B., Morrissey E., O'Connor D. T., Norepinephrine clearance, chromogranin A and dopamine β hydroxylase in renal failure. Kidney International 1990 37 5 1357 1362 2-s2.0-0025349240
17. Sturani A., Degli Esposti E., De March A., Santoro A., Fuschini G., Zuccalà A., Chiarini C., Flamigni C., Zucchelli P., Dopaminergic control of sympathetic activity and blood pressure in haemodialysis patients. Proceedings of the European Dialysis and Transplant Association 1983 20 156 160 2-s2.0-0020998277
18. Brotman D. J., Bash L. D., Qayyum R., Crews D., Whitsel E. A., Astor B. C., Coresh J., Heart rate variability predicts ESRD and CKD-related hospitalization. Journal of the American Society of Nephrology 2010 21 9 1560 1570 2-s2.0-77956548299 10.1681/ASN.2009111112
19. Siddiqi L., Prakken N. H., Velthuis B. K., Cramer M. J., Oey P. L., Boer P., Bots M. L., Blankestijn P. J., Sympathetic activity in chronic kidney disease patients is related to left ventricular mass despite antihypertensive treatment. Nephrology Dialysis Transplantation 2010 25 10 3272 3277 2-s2.0-77957220275 10.1093/ndt/gfq175
20. Akiyama-Uchida Y., Ashizawa N., Ohtsuru A., Seto S., Tsukazaki T., Kikuchi H., Yamashita S., Yano K., Norepinephrine enhances fibrosis mediated by TGF- β in cardiac fibroblasts. Hypertension 2002 40 2 148 154 2-s2.0-0036324006 10.1161/01.HYP.0000025443.61926.12
21. Mejía-Rodríguez O., Alvarez-Aguilar C., Ledesma-Ramirez M., Paniagua-Sierra R., Therapeutic effect of bromocriptine together with the established treatment for hypertension in patients undergoing peritoneal dialysis. Proceedings of the Western Pharmacology Society 2004 47 122 124 2-s2.0-9444244431
22. Mejía-Rodríguez O., Alvarez-Aguilar C., Vega-Gómez H. E., Belio-Caro F., Vargas-Espinosa J. M., Paniagua-Sierra J. R., Bromocriptine induces regression of left ventricular hypertrophy in peritoneal dialysis patients. Proceedings of the Western Pharmacology Society 2005 48 122 125 2-s2.0-30144433170
23. Degli Esposti E., Sturani A., Santoro A., Effect of bromocriptine treatment on prolactin, noradrenaline and blood pressure in hypertensive haemodialysis patients. Clinical Science 1985 69 1 51 56 2-s2.0-0021840363
24. Pijl H., Ohashi S., Matsuda M., Miyazaki Y., Mahankali A., Kumar V., Pipek R., Iozzo P., Lancaster J. L., Cincotta A. H., DeFronzo R. A., Bromocriptine: a novel approach to the treatment of type 2 diabetes. Diabetes Care 2000 23 8 1154 1161 2-s2.0-0033861067
25. Aminorroaya A., Janghorbani M., Ramezani M., Haghighi S., Amini M., Does bromocriptine improve glycemic control of obese type-2 diabetics? Hormone Research 2004 62 2 55 59 2-s2.0-4644244089 10.1159/000078932
26. Scranton R., Cincotta A., Bromocriptine unique formulation of a dopamine agonist for the treatment of type 2 diabetes. Expert Opinion on Pharmacotherapy 2010 11 2 269 279 2-s2.0-76749161800 10.1517/14656560903501544
27. Grubb A., Björk J., Lindström V., Sterner G., Bondesson P., Nyman U., A cystatin C-based formula without anthropometric variables estimates glomerular filtration rate better than creatinine clearance using the Cockcroft-Gault formula. Scandinavian Journal of Clinical and Laboratory Investigation 2005 65 2 153 162 2-s2.0-17644380635 10.1080/00365510510013596
28. Cincotta A. H., Meier A. H., Cincotta M. J., Bromocriptine improves glycaemic control and serum lipid profile in obese Type 2 diabetic subjects: a new approach in the treatment of diabetes. Expert Opinion on Investigational Drugs 1999 8 10 1683 1707 2-s2.0-0032844650 10.1517/13543784.8.10.1683
29. Ksiazek A., Załuska W., Sympathetic overactivity in uremia. Journal of Renal Nutrition 2008 18 1 118 121 2-s2.0-37049034231 10.1053/j.jrn.2007.10.024
30. Kagan A., Gertler A., Ulman M., Bar-Khayim Y., Serum levels and peritoneal loss of prolactin in CAPD patients. Advances in Peritoneal Dialysis. Conference on Peritoneal Dialysis 1991 7 247 252 2-s2.0-0025935703
31. Wang G.-J., Volkow N. D., Logan J., Pappas N. R., Wong C. T., Zhu W., Netusll N., Fowler J. S., Brain dopamine and obesity. The Lancet 2001 357 9253 354 357 2-s2.0-0035798931 10.1016/S0140-6736(00)03643-6
32. IJzerman R. G., Stehouwer C. D. A., de Geus E. J., van Weissenbruch M. M., Delemarre-van de Waal H. A., Boomsma D. I., Low birth weight is associated with increased sympathetic Activity: dependence on genetic factors. Circulation 2003 108 5 566 571 2-s2.0-0042575121 10.1161/01.CIR.0000081778.35370.1B
33. Ghosh S. S., Krieg R. J., Sica D. A., Wang R., Fakhry I., Gehr T., Cardiac hypertrophy in neonatal nephrectomized rats: the role of the sympathetic nervous system. Pediatric Nephrology 2009 24 2 367 377 2-s2.0-58149156562 10.1007/s00467-008-0978-8
34. Kamath V., Jones C. N., Yip J. C., Varasteh B. B., Cincotta A. H., Reaven G. M., Chen Y.-D. I., Effects of a quick-release form of bromocriptine (Ergoset) on fasting and postprandial plasma glucose, insulin, lipid, and lipoprotein concentrations in obese nondiabetic hyperinsulinemic women. Diabetes Care 1997 20 11 1697 1701 2-s2.0-0030829193
35. Perlini S., Palladini G., Ferrero I., Tozzi R., Fallarini S., Facoetti A., Nano R., Clari F., Busca G., Fogari R., Ferrari A. U., Sympathectomy or doxazosin, but not propranolol, blunt myocardial interstitial fibrosis in pressure-overload hypertrophy. Hypertension 2005 46 5 1213 1218 2-s2.0-27444436450 10.1161/01.HYP.0000185689.65045.4c
36. Gaziano J. M., Cincotta A. H., O'Connor C. M., Ezrokhi M., Rutty D., Ma Z. J., Scranton R. E., Randomized clinical trial of quick-release bromocriptine among patients with type 2 diabetes on overall safety and cardiovascular outcomes. Diabetes Care 2010 33 7 1503 1508 2-s2.0-77958179761 10.2337/dc09-2009
37. McMurray R., Keisler D., Kanuckel K., Izui S., Walker S. E., Prolactin influences autoimmune disease activity in the female B/W mouse. Journal of Immunology 1991 147 11 3780 3787 2-s2.0-0025748798
38. Miranda J. M., Prieto R. E., Paniagua R., Garcia G., Amato D., Barile L., Jara L. J., Clinical significance of serum and urine prolactin levels in lupus glomerulonephritis. Lupus 1998 7 6 387 391 2-s2.0-0031661699 10.1191/096120398678920307
39. Walker S. E., Treatment of systemic lupus erythematosus with bromocriptine. Lupus 2001 10 3 197 202 2-s2.0-0035047508 10.1191/ 096120301666625458
40. Defronzo R. A., Bromocriptine: a sympatholytic, D2-dopamine agonist for the treatment of type 2 diabetes. Diabetes Care 2011 34 6 789 794 2-s2.0-80052010890 10.2337/dc11-er06